Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization https://pubmed.ncbi.nlm.nih.gov/32955939/
[6]. Kosiborod, M.N., et al., Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med, 2024. 390(15): p. 1394-1407. [7]. Kosiborod, M.N., et al., Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N ...
Heart failureMajor adverse cardiovascular eventsGlucagon-like peptide-1 receptor agonists (GLP1-ra) have shown to reduce cardiovascular (CV) events in patients with diabetes, including heart failure (HF) hospitalizations. However, whether such benefit consistently occurs in patients with history of HF ...
HFpEF-DM预计将于2023年第四季度完成,如果研究取得积极成果,诺和诺德预计将于2024年上半年在美国和欧盟申请批准Wegovy标签更新。 参考来源:Semaglutide 2.4 mg shows large reductions in heart failure-related symptoms and physical limitations in people with heart failure with preserved ejection fraction and obesity....
Lilly Investors. Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity. News release. August 1, 2024. Accessed August 6, 2024. 注:以上资讯来...
1. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21; 389(12): 1069-1084. 2. Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J....
Lilly Investors. Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity. News release. August 1, 2024. Accessed August 6, 2024. 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新...
Heart Failure with Preserved Ejection Fraction (HFpEF) represents a significant challenge in modern cardiovascular medicine, characterized by diastolic dys
The authors wrote, "the purpose of this clinical practice guide is to offer unified, multi-society guidance for safely managing patients needing GLP-1RA therapy regardless of indication, which currently includes type 2 diabetes, overweight and obesity, andheart failure, during the periprocedural period...
20. Fu EL, Patorno E, Everett BM, et al.. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. Eur Heart J 2023;44:2216-30. 10.1093/eur...